Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging | 18 | 2022 | 2222 | 1.240 |
Why?
|
| Contrast Media | 16 | 2020 | 594 | 1.170 |
Why?
|
| Chest Pain | 4 | 2020 | 151 | 1.100 |
Why?
|
| Heart Atria | 2 | 2016 | 206 | 1.020 |
Why?
|
| Computed Tomography Angiography | 6 | 2021 | 424 | 0.980 |
Why?
|
| Heart Defects, Congenital | 6 | 2019 | 596 | 0.940 |
Why?
|
| Magnetic Resonance Angiography | 7 | 2021 | 181 | 0.830 |
Why?
|
| Myocardial Infarction | 6 | 2017 | 807 | 0.790 |
Why?
|
| Gadolinium | 3 | 2018 | 88 | 0.740 |
Why?
|
| Tomography, X-Ray Computed | 17 | 2021 | 2323 | 0.730 |
Why?
|
| Myocardial Ischemia | 1 | 2021 | 172 | 0.720 |
Why?
|
| Sick Sinus Syndrome | 1 | 2019 | 18 | 0.710 |
Why?
|
| Sinus of Valsalva | 1 | 2019 | 9 | 0.700 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2019 | 45 | 0.680 |
Why?
|
| Heart | 8 | 2021 | 850 | 0.670 |
Why?
|
| Diagnostic Imaging | 7 | 2021 | 201 | 0.670 |
Why?
|
| Image Enhancement | 2 | 2017 | 143 | 0.580 |
Why?
|
| Myocardium | 9 | 2018 | 1204 | 0.570 |
Why?
|
| Hemangiosarcoma | 1 | 2016 | 23 | 0.570 |
Why?
|
| Heart Neoplasms | 1 | 2016 | 33 | 0.560 |
Why?
|
| Sarcoma, Ewing | 1 | 2015 | 26 | 0.530 |
Why?
|
| Coronary Thrombosis | 1 | 2015 | 45 | 0.530 |
Why?
|
| Organometallic Compounds | 6 | 2016 | 95 | 0.520 |
Why?
|
| Coronary Angiography | 9 | 2022 | 866 | 0.480 |
Why?
|
| Societies, Medical | 4 | 2021 | 403 | 0.420 |
Why?
|
| Coronary Artery Disease | 3 | 2022 | 696 | 0.390 |
Why?
|
| Humans | 47 | 2022 | 68525 | 0.360 |
Why?
|
| Magnetic Resonance Imaging, Cine | 4 | 2017 | 83 | 0.340 |
Why?
|
| Aortography | 2 | 2021 | 72 | 0.340 |
Why?
|
| Aorta, Thoracic | 2 | 2021 | 211 | 0.320 |
Why?
|
| Peripheral Arterial Disease | 2 | 2020 | 83 | 0.310 |
Why?
|
| Vascular Calcification | 2 | 2020 | 131 | 0.300 |
Why?
|
| Female | 27 | 2022 | 38015 | 0.290 |
Why?
|
| Preoperative Care | 2 | 2019 | 275 | 0.280 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 1172 | 0.280 |
Why?
|
| Aortic Diseases | 2 | 2019 | 113 | 0.280 |
Why?
|
| Transcatheter Aortic Valve Replacement | 2 | 2018 | 90 | 0.270 |
Why?
|
| Aortic Valve | 3 | 2018 | 249 | 0.260 |
Why?
|
| Adult | 15 | 2020 | 21375 | 0.260 |
Why?
|
| Middle Aged | 20 | 2021 | 21119 | 0.260 |
Why?
|
| Myocarditis | 2 | 2014 | 49 | 0.250 |
Why?
|
| Prospective Studies | 8 | 2021 | 3702 | 0.250 |
Why?
|
| Cardiac Imaging Techniques | 2 | 2021 | 35 | 0.230 |
Why?
|
| Reproducibility of Results | 9 | 2021 | 2077 | 0.230 |
Why?
|
| Aortic Valve Stenosis | 2 | 2015 | 177 | 0.210 |
Why?
|
| Respiration | 2 | 2019 | 91 | 0.210 |
Why?
|
| Vasculitis | 1 | 2021 | 33 | 0.210 |
Why?
|
| Aged | 15 | 2021 | 14842 | 0.210 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2019 | 333 | 0.210 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 38 | 0.200 |
Why?
|
| Male | 25 | 2021 | 37281 | 0.200 |
Why?
|
| Predictive Value of Tests | 8 | 2021 | 1465 | 0.200 |
Why?
|
| Coronary Vessels | 2 | 2017 | 313 | 0.200 |
Why?
|
| Angiography, Digital Subtraction | 2 | 2020 | 63 | 0.190 |
Why?
|
| Upper Extremity Deep Vein Thrombosis | 1 | 2020 | 2 | 0.190 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2021 | 100 | 0.190 |
Why?
|
| Standard of Care | 1 | 2020 | 22 | 0.190 |
Why?
|
| Radiology | 1 | 2021 | 97 | 0.180 |
Why?
|
| Hemoptysis | 2 | 2017 | 28 | 0.180 |
Why?
|
| Costs and Cost Analysis | 1 | 2020 | 193 | 0.180 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2021 | 134 | 0.180 |
Why?
|
| Lower Extremity | 2 | 2020 | 153 | 0.170 |
Why?
|
| Electrocardiography | 6 | 2022 | 601 | 0.170 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 438 | 0.170 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2019 | 116 | 0.160 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2017 | 237 | 0.150 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 2 | 2015 | 91 | 0.150 |
Why?
|
| Aneurysm, Ruptured | 1 | 2017 | 40 | 0.150 |
Why?
|
| Young Adult | 6 | 2020 | 5708 | 0.150 |
Why?
|
| Feasibility Studies | 4 | 2021 | 652 | 0.150 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2017 | 61 | 0.150 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2016 | 689 | 0.140 |
Why?
|
| Hematemesis | 1 | 2016 | 14 | 0.140 |
Why?
|
| Diagnosis, Differential | 6 | 2021 | 1139 | 0.140 |
Why?
|
| Cardiac Catheterization | 3 | 2019 | 419 | 0.140 |
Why?
|
| Cardiac-Gated Imaging Techniques | 2 | 2015 | 60 | 0.140 |
Why?
|
| Aorta, Abdominal | 1 | 2017 | 97 | 0.140 |
Why?
|
| Coronary Disease | 2 | 2009 | 358 | 0.140 |
Why?
|
| Aged, 80 and over | 8 | 2021 | 4843 | 0.140 |
Why?
|
| Analysis of Variance | 2 | 2017 | 1039 | 0.140 |
Why?
|
| Meglumine | 1 | 2015 | 16 | 0.130 |
Why?
|
| Heart Diseases | 1 | 2018 | 276 | 0.130 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2022 | 756 | 0.130 |
Why?
|
| Observer Variation | 4 | 2017 | 330 | 0.130 |
Why?
|
| Pulmonary Artery | 1 | 2017 | 323 | 0.130 |
Why?
|
| Eosinophilia | 1 | 2014 | 47 | 0.130 |
Why?
|
| Heart Aneurysm | 1 | 2014 | 21 | 0.120 |
Why?
|
| Aspergillosis | 1 | 2014 | 20 | 0.120 |
Why?
|
| Pentetic Acid | 5 | 2016 | 18 | 0.120 |
Why?
|
| After-Hours Care | 1 | 2014 | 17 | 0.120 |
Why?
|
| Pancreas | 1 | 2015 | 225 | 0.120 |
Why?
|
| Thoracic Diseases | 1 | 2014 | 10 | 0.120 |
Why?
|
| Williams Syndrome | 1 | 2013 | 13 | 0.120 |
Why?
|
| Gadolinium DTPA | 2 | 2011 | 48 | 0.120 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2014 | 116 | 0.110 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 711 | 0.110 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2017 | 450 | 0.110 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 277 | 0.110 |
Why?
|
| Adolescent | 7 | 2020 | 8903 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2015 | 332 | 0.100 |
Why?
|
| Coronary Stenosis | 1 | 2014 | 246 | 0.100 |
Why?
|
| Iopamidol | 2 | 2009 | 37 | 0.100 |
Why?
|
| Heart Valve Prosthesis | 1 | 2012 | 222 | 0.100 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2012 | 164 | 0.100 |
Why?
|
| Dilatation, Pathologic | 2 | 2021 | 58 | 0.090 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 1989 | 15 | 0.090 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2009 | 6 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2014 | 657 | 0.090 |
Why?
|
| United States | 4 | 2021 | 7335 | 0.080 |
Why?
|
| Triiodobenzoic Acids | 1 | 2008 | 28 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2014 | 596 | 0.080 |
Why?
|
| Constriction, Pathologic | 2 | 2020 | 236 | 0.080 |
Why?
|
| Ventricular Function, Right | 1 | 2009 | 103 | 0.080 |
Why?
|
| Iohexol | 1 | 2008 | 82 | 0.080 |
Why?
|
| Creatinine | 1 | 2008 | 243 | 0.080 |
Why?
|
| User-Computer Interface | 1 | 2009 | 230 | 0.080 |
Why?
|
| Sensitivity and Specificity | 3 | 2020 | 1753 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 1989 | 329 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 1 | 2008 | 274 | 0.080 |
Why?
|
| Time Factors | 4 | 2021 | 4655 | 0.070 |
Why?
|
| Adenocarcinoma | 2 | 2009 | 475 | 0.070 |
Why?
|
| Atherosclerosis | 1 | 2008 | 204 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 938 | 0.070 |
Why?
|
| Retrospective Studies | 6 | 2020 | 7264 | 0.070 |
Why?
|
| Infant | 3 | 2019 | 2891 | 0.070 |
Why?
|
| Fatal Outcome | 2 | 2017 | 164 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2019 | 3185 | 0.070 |
Why?
|
| Kidney Diseases | 1 | 2008 | 307 | 0.070 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 3 | 2017 | 373 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2016 | 346 | 0.060 |
Why?
|
| Dogs | 3 | 2011 | 490 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 778 | 0.050 |
Why?
|
| Disease Progression | 2 | 2021 | 1037 | 0.050 |
Why?
|
| Radiography | 2 | 2017 | 572 | 0.050 |
Why?
|
| Purines | 1 | 2021 | 39 | 0.050 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2021 | 3 | 0.050 |
Why?
|
| Child | 3 | 2019 | 6400 | 0.050 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2021 | 137 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2021 | 190 | 0.050 |
Why?
|
| Biopsy | 2 | 2014 | 539 | 0.050 |
Why?
|
| Acute Pain | 1 | 2020 | 35 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 1851 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2021 | 185 | 0.040 |
Why?
|
| Upper Extremity | 1 | 2020 | 112 | 0.040 |
Why?
|
| Movement | 1 | 2019 | 179 | 0.040 |
Why?
|
| Disease Models, Animal | 3 | 2011 | 2550 | 0.040 |
Why?
|
| Graves Disease | 2 | 1988 | 8 | 0.040 |
Why?
|
| HLA-DR Antigens | 2 | 1988 | 41 | 0.040 |
Why?
|
| Thoracic Cavity | 1 | 2017 | 2 | 0.040 |
Why?
|
| Heart Sounds | 1 | 2017 | 3 | 0.040 |
Why?
|
| Treatment Refusal | 1 | 2017 | 40 | 0.040 |
Why?
|
| Aneurysm, False | 1 | 2017 | 60 | 0.040 |
Why?
|
| Regional Blood Flow | 1 | 2017 | 168 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 2017 | 172 | 0.040 |
Why?
|
| Magnetic Fields | 1 | 2016 | 21 | 0.030 |
Why?
|
| Animals | 5 | 2013 | 20877 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 546 | 0.030 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2015 | 93 | 0.030 |
Why?
|
| Autopsy | 1 | 2014 | 56 | 0.030 |
Why?
|
| Echocardiography | 1 | 2017 | 515 | 0.030 |
Why?
|
| Necrosis | 1 | 2014 | 239 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2015 | 453 | 0.030 |
Why?
|
| Fibrosis | 1 | 2014 | 371 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2018 | 1329 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2015 | 586 | 0.030 |
Why?
|
| Acute Disease | 1 | 2014 | 658 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 2014 | 253 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2017 | 2453 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2012 | 301 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2015 | 738 | 0.020 |
Why?
|
| Thyroid Gland | 2 | 1988 | 67 | 0.020 |
Why?
|
| Heart Rate | 1 | 2012 | 568 | 0.020 |
Why?
|
| CD5 Antigens | 1 | 1989 | 5 | 0.020 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1989 | 6 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 1989 | 49 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 1194 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1989 | 77 | 0.020 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1989 | 89 | 0.020 |
Why?
|
| HLA Antigens | 1 | 1989 | 82 | 0.020 |
Why?
|
| Methimazole | 1 | 1988 | 9 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 2093 | 0.020 |
Why?
|
| Patient Selection | 1 | 2012 | 592 | 0.020 |
Why?
|
| Blood Vessels | 1 | 2008 | 102 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2008 | 134 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 306 | 0.020 |
Why?
|
| Thyroid Neoplasms | 1 | 1989 | 68 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2008 | 215 | 0.020 |
Why?
|
| Receptors, Thyrotropin | 1 | 1987 | 7 | 0.020 |
Why?
|
| South Carolina | 1 | 2014 | 2750 | 0.020 |
Why?
|
| Carcinoma | 1 | 1989 | 215 | 0.020 |
Why?
|
| HLA-D Antigens | 1 | 1987 | 20 | 0.020 |
Why?
|
| Artifacts | 1 | 2008 | 125 | 0.020 |
Why?
|
| Risk | 1 | 2008 | 563 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 2004 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 737 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 371 | 0.020 |
Why?
|
| Microspheres | 1 | 2006 | 59 | 0.020 |
Why?
|
| Perfusion | 1 | 2006 | 131 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 1032 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2008 | 705 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2006 | 155 | 0.020 |
Why?
|
| Ischemia | 1 | 2006 | 229 | 0.020 |
Why?
|
| Autoantibodies | 1 | 1987 | 434 | 0.020 |
Why?
|
| Reperfusion Injury | 1 | 2006 | 320 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 5719 | 0.010 |
Why?
|
| Mice | 1 | 2009 | 8472 | 0.010 |
Why?
|
| Interferon-gamma | 2 | 1988 | 241 | 0.010 |
Why?
|
| Carcinoma, Papillary | 1 | 1989 | 35 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1989 | 80 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 1989 | 132 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1989 | 179 | 0.010 |
Why?
|
| Alleles | 1 | 1989 | 386 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1988 | 765 | 0.000 |
Why?
|
| Thyrotropin | 1 | 1987 | 49 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 1988 | 481 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 1989 | 595 | 0.000 |
Why?
|